Top 5 Future Oncology articles – May 2021

In this latest instalment of his regular monthly column, Louis Gautier, Commissioning Editor of Future Oncology, exclusively shares his top 5 picks from the recent journal issues, which we have made freely available for you, Oncology Central members! Check out Louis’ highlights below. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial  The results of the ARAMIS trial were published in September of 2020, reporting that darolutamide (Nubeqa®) in combination with hormone therapy was effective at prolonging survival and decreased the risk of death from nonmetastatic, castration-resistant prostate cancer by 31% compared with placebo.  This open access plain language summary reports the...